Full-Time
Confirmed live in the last 24 hours
Develops medical devices for vascular conditions
No salary listed
Junior, Mid
No H1B Sponsorship
Turin, Metropolitan City of Turin, Italy
This is a hybrid position, indicating a mix of remote and in-office work.
Upload your resume to see how it matches 9 keywords from the job description.
PDF, DOC, DOCX, up to 4 MB
Penumbra Inc. specializes in creating medical devices for treating neurovascular and peripheral vascular conditions. Their products, such as the Penumbra System and Indigo System, are designed to assist healthcare professionals in addressing issues like stroke and other vascular diseases. These devices work by providing advanced tools for interventions in neurology and vascular surgery, helping to improve patient outcomes. Unlike many competitors, Penumbra focuses specifically on these specialized areas and invests heavily in research and development to enhance their offerings. The company's goal is to deliver high-quality medical devices that meet the needs of healthcare providers and improve the treatment of vascular conditions.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Alameda, California
Founded
2004
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Parental Leave
Paid Vacation
Paid Sick Leave
Paid Holidays
Penumbra announces Red 72 Silver Label product featuring company's latest engineering enhancements.
ALAMEDA, Calif., April 3, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the first quarter 2025 after market close on Wednesday, April 23, 2025 at 4:30 PM Eastern Time. A press release with first quarter 2025 financial results will be issued after market close that day.Webcast & Conference Call InformationThe conference call can be accessed live over the phone by dialing (888) 596-4144 (conference id: 6572573), or the webcast can be accessed on the "Events and Presentations" section under the "Investors" tab of the Company's website at www.penumbrainc.com. The webcast will be available on the Company's website for at least two weeks following the completion of the call.About PenumbraPenumbra, Inc., the world's leading thrombectomy company, is focused on developing the most innovative technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism such as pulmonary embolism, and acute limb ischemia. Our broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe with speed, safety and simplicity. By pioneering these innovations, we support healthcare providers, hospitals and clinics in more than 100 countries, working to improve patient outcomes and quality of life
Latest data on Penumbra's CAVT technology to be presented at SIR 2025: STRIDE, STRIKE-PE, and more.
Penumbra launches Access25 delivery microcatheter designed for brain aneurysm access.
Penumbra recently launched the ACCESS25 Delivery Microcatheter, a single lumen medical device designed to aid physicians in accessing the neurovasculature for the delivery of Penumbra's advanced .020" coil platform.